New asthma drug candidate IBI3002 begins early safety testing
NCT ID NCT06947408
First seen Jun 09, 2026 · Last updated Jun 11, 2026 · Updated 1 time
Summary
This early-stage study tested the safety of a new drug called IBI3002 in 44 healthy volunteers and people with asthma. Participants received either the drug or a placebo, and researchers monitored for side effects. The goal was to find safe dose levels and understand how the drug moves through the body. This is a first step to see if IBI3002 could one day help control asthma symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China-japan Friendship Hosipital
Beijing, Beijing Municipality, 100192, China
Conditions
Explore the condition pages connected to this study.